Christopher Kirkham: Could Platelet Activation Become a Liability for Your Antibody Programme?
Christopher Kirkham, Group Leader in Ex Vivo Biology at IQVIA Laboratories, shared a post on LinkedIn:
“Could platelet activation become a liability for your antibody programme?
Platelet safety is often overlooked until a signal emerges during development. However, unintended interactions with platelets can have significant consequences, including platelet depletion, activation and thrombotic complications.
Early assessment of platelet binding, activation and function can help identify potential liabilities before they become costly development challenges.
At IQVIA Laboratories, we combine flow cytometry and aggregometry to provide a comprehensive ex vivo assessment of antibody-mediated platelet responses, supporting more informed candidate selection and risk assessment earlier in development.”
Stay updated with Hemostasis Today.
-
Sep 20, 2026, 09:51Ceasovschih Alexandr: A Closer Look at Lipid Disorders in CKM Syndrome
-
Sep 20, 2026, 09:05World Stroke Academy: Can Adjunct IAT Improve Tissue Reperfusion?
-
Sep 20, 2026, 06:46Neeraj Songara: From Donated Blood to Engineered Therapeutics
-
Sep 20, 2026, 06:24Louise St. Germain Bannon: Improving Awareness and Care for Women Across the Lifespan
-
Sep 20, 2026, 05:17Maxime Dely: When ABO Compatibility Isn’t Enough for Safe Transfusion
-
Sep 20, 2026, 04:54William Aird: What Does a Complete History and Physical Really Mean?
-
Sep 20, 2026, 04:34Hons Saurabh Kaushik: Why Uncontrolled LDL Can Be Harmful
-
Sep 20, 2026, 03:58Salih Ehsan: The Complexities of HbF and HbA2
-
Sep 20, 2026, 03:22The Voices of People Living With Bleeding Disorders – EHC